Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

455

Enrollment

INDUSTRY

Sponsor class

Conditions

Leiomyosarcoma

Interventions

DRUG: Lurbinectedin
DRUG: Doxorubicin

Sponsor

PharmaMar